MedTrace Logo

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

NCT05602792 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2022-11-02

No results posted yet for this study

Summary

A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor
  • Sarcoma
  • HNSCC
  • Breast Cancer
  • Esophagus Cancer
  • NSCLC
  • Non-melanoma Skin Cancer

Interventions

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with advanced solid tumors.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with sarcoma.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with breast cancer.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with esophagus cancer.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with lung cancer.

BIOLOGICAL

T3011

T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.

Sponsors & Collaborators

  • ImmVira Pharma Co. Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-21
Primary Completion
2023-07-31
Completion
2024-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05602792 on ClinicalTrials.gov